Press Releases

Date Title and Summary View
Toggle Summary Study Results Confirm T-SPOT®.TB is Cost-Effective in TB Control Programmes
Study Results Confirm T-SPOT ® .TB is Cost-Effective in TB Control Programmes Oxford, UK; 9th October 2007 - Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating that T-SPOT. TB is cost-effective when used in contact tracing
View HTML
Toggle Summary Study Results Suggest the Utility of T-SPOT®.TB in Monitoring Treatment for Latent TB Infection (LTBI)
Study Results Suggest the Utility of T-SPOT ® .TB in Monitoring Treatment for Latent TB Infection (LTBI) Oxford, UK; 10th September 2007 - Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating the potential use of T-SPOT.
View HTML
Toggle Summary Report Highlights the Reliability of T-SPOT®.TB Following Administration of the Tuberculin Skin Test
Report Highlights the Reliability of T-SPOT ® .TB Following Administration of the Tuberculin Skin Test Oxford, UK; 10th August 2007 - Oxford Immunotec Ltd., the T cell measurement company, today announced the report of a recent study demonstrating the reliability of T-SPOT.
View HTML
Toggle Summary Oxford Immunotec Ltd Wins Best Healthcare Innovation Award and Recieves the Additional Accolade of Overall Winner of the Martin and Audrey Wood Enterprise Awards 2007
PRESS RELEASE - 4 May 2007 Winners celebrate Success at Martin and Audrey Wood Enterprise Awards Celebrating Innovators and Entrepreneurs
View HTML
Toggle Summary Study Results Confirm Utility of T-SPOT®.TB as a Rapid Rule Out Test for Tuberculosis Disease
Study Results Confirm Utility of T-SPOT ® .TB as a Rapid Rule Out Test for Tuberculosis Disease Oxford, UK; 19th April 2007 - Oxford Immunotec Ltd, the T cell measurement company, today announced the publication of a recent study demonstrating the use of T-SPOT.
View HTML
Toggle Summary Oxford Immunotec Grants License Over T-SPOT® Technology to Sanofi Pasteur for Human Vaccine Research
Oxford Immunotec Grants License Over T-SPOT ® Technology to Sanofi Pasteur for Human Vaccine Research Oxford, UK; 04 April 2007 - Oxford Immunotec Ltd, the T cell measurement company, today announces that:  it has licenced its technology to sanofi pasteur, the vaccines business of the
View HTML
Toggle Summary Study Results Confirm Superior Efficacy of T-SPOT®TB Over QuantiFERON® and the TST in Detecting TB Infection in HIV Patients
Study Results Confirm Superior Efficacy of T-SPOT ® TB Over QuantiFERON® and the TST in Detecting TB Infection in HIV Patients Oxford, UK; 28th March 2007 - Oxford Immunotec Ltd, the T cell measurement company, today announced the publication of a recent study supporting the superior
View HTML
Toggle Summary Oxford Immunotec Announces Appointment of President – North America and Filing for FDA Approval for T-SPOT®.TB
Oxford Immunotec Announces Appointment of President – North America and Filing for FDA Approval for T-SPOT ® .TB Oxford, UK; 19th March 2007 - Oxford Immunotec Ltd, the T cell measurement company, today announces that: it has appointed Jeff Schroeder as President of its North American
View HTML
Toggle Summary Study Results Support Use of T-SPOT®.TB to Monitor Latent TB Infection
Study Results Support Use of T-SPOT ® .TB to Monitor Latent TB Infection Oxford, UK; 5th March 2007 - Oxford Immunotec Ltd, the T cell measurement company, today announced the publication of a recent study demonstrating the potential use of T-SPOT.
View HTML
Toggle Summary Study Results Confirm Superior Performance of Oxford Immunotec Ltd's T-SPOT®.TB Over Other Diagnostic Tests for Tuberculosis
Study Results Confirm Superior Performance of Oxford Immunotec Ltd's T-SPOT ® .TB Over Other Diagnostic Tests for Tuberculosis Oxford, UK; 02 August 2006 - Oxford Immunotec Ltd, the T cell measurement company, has today announced the outcome of two studies comparing its T-SPOT.
View HTML